{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:23:02Z","timestamp":1791516182556,"version":"4.3.4"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>Boron Neutron Capture Therapy (BNCT) has gained popularity in recent years, with over 500 treatment courses performed in Taiwan since 2017. Traditionally, the tumor-to-normal tissue ratio (T\/N ratio) is assessed using SUV measurements from 4-borono-2-(18) F-fluoro-phenylalanine (F-BPA) PET, allowing for precise tumor boron concentration estimation when serum boron levels are measured on the day of treatment. However, limited accessibility to F-BPA PET complicates dose calculations, and in its absence, a fixed T\/N ratio of 3 is used in treatment planning. Fluciclovine PET has recently been explored as an alternative, as both fluciclovine and BPA share the L-type amino acid transporter 1 (LAT-1) transporter, although fluciclovine can also be transported via alanine-serine-cysteine transporter 2 (ASCT2). However, its accuracy in reflecting BPA distribution and its correlation with treatment response remain uncertain.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods:<\/jats:title>\n            <jats:p>Since June 2022, fluciclovine PET has been used for brain tumor evaluation in Taiwan. By June 2024, 80 brain tumor patients underwent pre-BNCT assessment with fluciclovine PET. After excluding those who received a second treatment course, 44 patients were analyzed. The average T\/N ratio in this cohort was 4.6, higher than reported averages for F-BPA PET (2.5 for head and neck tumors, 3 for brain tumors). The tumor response rate was defined as patients achieving either a complete or partial response, as evaluated by experienced neuroradiologists. Patients were categorized based on response achievement, and potential prognostic factors were compared.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The mean T\/N ratio of fluciclovine PET was 4.61\u00b11.43 (range: 2.58\u20138.86). Among 15 patients who underwent follow-up fluciclovine PET 3 months post-BNCT, the mean T\/N ratio decreased significantly to 2.85\u00b11.16 (range: 1.00\u20135.47). Treatment response assessment at 3 months post-BNCT revealed that 4 patients achieved complete response (CR), 26 had partial response (PR), 5 exhibited stable disease (SD), and 9 experienced progressive disease (PD). Responders had significantly smaller tumors compared with nonresponders (35.74 vs. 83.83\u00a0cm\u00b3, <jats:italic toggle=\"yes\">p<\/jats:italic>=0.009) and received higher minimum tumor doses (18.50 vs. 12.13\u00a0GyE, <jats:italic toggle=\"yes\">p<\/jats:italic>=0.033). In addition, a significant decline in T\/N ratio was observed following BNCT, decreasing from 4.602\u00b10.368 pretreatment to 2.847\u00b10.300 at 3 months post-treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Our findings suggest that while fluciclovine PET may provide an estimate of BPA uptake, it is not a reliable predictor of treatment response. However, it remains an effective tool for assessing treatment effect following BNCT. Further studies are necessary to identify key prognostic factors for selecting BNCT candidates and to determine whether fluciclovine PET can effectively predict BNCT outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006047","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T19:00:07Z","timestamp":1752260407000},"page":"895-901","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Clinical Utility of Fluciclovine PET in BNCT for Recurrent High-grade Glioma"],"prefix":"10.1097","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0972-713X","authenticated-orcid":false,"given":"Tien-Li","family":"Lan","sequence":"first","affiliation":[{"name":"Department of Heavy Particles and Radiation Oncology, Taipei Veterans General Hospital"},{"name":"School of Medicine, National Yang Ming Chiao Tung University"},{"name":"Department of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko-Han","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Taipei Veterans General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3946-7540","authenticated-orcid":false,"given":"Yi-Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Heavy Particles and Radiation Oncology, Taipei Veterans General Hospital"},{"name":"School of Medicine, National Yang Ming Chiao Tung University"},{"name":"Department of Medical Imaging and Radiological Technology, Yuanpei University of Medical Technology, Hsinchu, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Ono","sequence":"additional","affiliation":[{"name":"BNCT Joint Clinical Institute, Osaka Medical and Pharmaceutical University, Takatsuki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8867-5683","authenticated-orcid":false,"given":"Chao-Yang","family":"Kuo","sequence":"additional","affiliation":[{"name":"Smart Healthcare Interdisciplinary College, National Taipei University of Nursing and Health Sciences, Taipei"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9196-4897","authenticated-orcid":false,"given":"Jinn-Jer","family":"Peir","sequence":"additional","affiliation":[{"name":"Institute of Nuclear Engineering and Science, National Tsing Hua University, Hsinchu, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Ming","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"R1-20250903","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.radonc.2020.11.001","article-title":"Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan (10B) for recurrent or locally advanced head and neck cancer (JHN002): an open-label phase II trial","volume":"155","author":"Hirose","year":"2021","journal-title":"Radiother Oncol"},{"key":"R2-20250903","doi-asserted-by":"crossref","first-page":"109212","DOI":"10.1016\/j.apradiso.2020.109212","article-title":"Boron neutron capture therapy for head and neck cancer: relevance of nuclear-cytoplasmic volume ratio and anti-tumor effect. A preliminary report","volume":"163","author":"Aihara","year":"2020","journal-title":"Appl Radiat Isot"},{"issue":"7-8 Suppl","key":"R3-20250903","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.apradiso.2009.03.015","article-title":"Survival benefit from boron neutron capture therapy for the newly diagnosed glioblastoma patients","volume":"67","author":"Kawabata","year":"2009","journal-title":"Appl Radiat Isot"},{"key":"R4-20250903","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-020-03586-6","article-title":"Boron neutron capture therapy for malignant brain tumors","volume":"149","author":"Miyatake","year":"2020","journal-title":"J Neurooncol"},{"key":"R5-20250903","doi-asserted-by":"crossref","first-page":"1272507","DOI":"10.3389\/fonc.2023.1272507","article-title":"Acral cutaneous malignant melanoma treated with linear accelerator-based boron neutron capture therapy system: a case report of first patient","volume":"13","author":"Igaki","year":"2023","journal-title":"Front Oncol"},{"key":"R6-20250903","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF03178777","article-title":"Boron neutron capture therapy (BNCT) for malignant melanoma with special reference to absorbed doses to the normal skin and tumor","volume":"26","author":"Fukuda","year":"2003","journal-title":"Australas Phys Eng Sci Med"},{"key":"R7-20250903","doi-asserted-by":"crossref","first-page":"21","DOI":"10.21037\/tro-20-10","article-title":"Boron neutron capture therapy as salvage treatment for recurrent papillary thyroid carcinoma\u2014a case report","volume":"4","author":"Pan","year":"2020","journal-title":"Ther Radiol Oncol"},{"key":"R8-20250903","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.radonc.2009.01.010","article-title":"Impact of accelerator-based boron neutron capture therapy (AB-BNCT) on the treatment of multiple liver tumors and malignant pleural mesothelioma","volume":"92","author":"Suzuki","year":"2009","journal-title":"Radiother Oncol"},{"key":"R9-20250903","doi-asserted-by":"crossref","first-page":"111715","DOI":"10.1016\/j.apradiso.2025.111715","article-title":"Boron neutron capture therapy (BNCT) for left axillary lymph node metastasis of recurrent breast cancer","volume":"219","author":"Fujimoto","year":"2025","journal-title":"Appl Radiat Isot"},{"key":"R10-20250903","doi-asserted-by":"crossref","first-page":"107276","DOI":"10.1016\/j.radmeas.2024.107276","article-title":"New technologies for beam spectrometry, quality assurance, real-time monitoring and microdosimetry in BNCT","volume":"177","author":"Kumada","year":"2024","journal-title":"Radiat Meas"},{"key":"R11-20250903","first-page":"334","article-title":"Salvage boron neutron capture therapy for malignant brain tumor patients in compliance with emergency and compassionate use: evaluation of 34 cases in Taiwan","volume":"10","author":"Chen","year":"2021","journal-title":"Biology (Basel)"},{"key":"R12-20250903","doi-asserted-by":"crossref","first-page":"109105","DOI":"10.1016\/j.apradiso.2020.109105","article-title":"Using salvage Boron Neutron Capture Therapy (BNCT) for recurrent malignant brain tumors in Taiwan","volume":"160","author":"Lan","year":"2020","journal-title":"Appl Radiat Isot"},{"key":"R13-20250903","doi-asserted-by":"crossref","first-page":"109143","DOI":"10.1016\/j.apradiso.2020.109143","article-title":"The overview and prospects of BNCT facility at Tsing Hua Open-pool reactor","volume":"161","author":"Jiang","year":"2020","journal-title":"Appl Radiat Isot"},{"key":"R14-20250903","first-page":"800","article-title":"NeuTHOR Station\u2014a novel integrated platform for monitoring BNCT clinical treatment, animal and cell irradiation study at THOR","volume":"13","author":"Huang","year":"2023","journal-title":"Life (Basel)"},{"key":"R15-20250903","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.21037\/qims-23-1769","article-title":"Prognostic assessment of 18F-boronophenylalanine positron emission tomography (BPA-PET) in salvage boron neutron capture therapy for malignant brain tumors","volume":"14","author":"Lin","year":"2024","journal-title":"Quant Imaging Med Surg"},{"key":"R16-20250903","doi-asserted-by":"crossref","first-page":"107964","DOI":"10.1016\/j.pharmthera.2021.107964","article-title":"Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics","volume":"230","author":"Kanai","year":"2022","journal-title":"Pharmacol Ther"},{"key":"R17-20250903","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13014-017-0949-y","article-title":"Dynamic changes in 18F-borono-L-phenylalanine uptake in unresectable, advanced, or recurrent squamous cell carcinoma of the head and neck and malignant melanoma during boron neutron capture therapy patient selection","volume":"13","author":"Morita","year":"2018","journal-title":"Radiat Oncol"},{"key":"R18-20250903","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13550-019-0518-5","article-title":"Correlation between 18F-1-amino-3-fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) uptake and expression of alanine-serine-cysteine-transporter 2 (ASCT2) and L-type amino acid transporter 1 (LAT1) in primary prostate cancer","volume":"9","author":"Saarinen","year":"2019","journal-title":"EJNMMI Res"},{"key":"R19-20250903","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s12149-021-01670-z","article-title":"Determining the extent of tumor resection at surgical planning with 18F-fluciclovine PET\/CT in patients with suspected glioma: multicenter phase III trials","volume":"35","author":"Wakabayashi","year":"2021","journal-title":"Ann Nucl Med"},{"key":"R20-20250903","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00259-019-04433-1","article-title":"18F-Fluciclovine (18F-FACBC) PET imaging of recurrent brain tumors","volume":"47","author":"Michaud","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R21-20250903","doi-asserted-by":"crossref","first-page":"852","DOI":"10.2967\/jnumed.122.264812","article-title":"Distinguishing progression from pseudoprogression in glioblastoma using 18F-fluciclovine PET","volume":"64","author":"Nabavizadeh","year":"2023","journal-title":"J Nucl Med"},{"key":"R22-20250903","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.apradiso.2004.05.066","article-title":"Characteristics of the new THOR epithermal neutron beam for BNCT","volume":"61","author":"Tung","year":"2004","journal-title":"Appl Radiat Isot"},{"key":"R24-20250903","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000469679","article-title":"Boron Neutron Capture Therapy of malignant gliomas","volume":"32","author":"Miyatake","year":"2018","journal-title":"Prog Neurol Surg"},{"key":"R25-20250903","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1200\/JCO.23.01059","article-title":"RANO 2.0: update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults","volume":"41","author":"Wen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2-4","key":"R26-20250903","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/rpd\/ncq511","article-title":"Microdosimetric evaluation of the neutron field for BNCT at Kyoto University reactor by using the PHITS code","volume":"143","author":"Baba","year":"2011","journal-title":"Radiat Prot Dosimetry"},{"key":"R27-20250903","doi-asserted-by":"crossref","first-page":"012015","DOI":"10.1088\/1742-6596\/1475\/1\/012015","article-title":"Radioactive isotope production in the fast neutron nuclear reactors","volume":"1475","author":"Risovanyi","year":"2020","journal-title":"J Phys Conf Ser"},{"key":"R28-20250903","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/18811248.1995.9731677","article-title":"Design studies of an epithermal neutron Beam for Neutron Capture Therapy at the Musashi Reactor","volume":"32","author":"Matsumoto","year":"1995","journal-title":"J Nucl Sci Technol"},{"key":"R29-20250903","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10147-019-01480-4","article-title":"Boron neutron capture therapy (BNCT): a unique role in radiotherapy with a view to entering the accelerator-based BNCT era","volume":"25","author":"Suzuki","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"R30-20250903","first-page":"vdab067","article-title":"Accelerator-based BNCT for patients with recurrent glioblastoma: a multicenter phase II study","volume":"3","author":"Kawabata","year":"2021","journal-title":"Neurooncol Adv"},{"issue":"1-4","key":"R31-20250903","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/rpd\/ncx218","article-title":"Development of a new multimodal Monte Carlo based treatment planning system","volume":"180","author":"Kumada","year":"2018","journal-title":"Radiat Prot Dosimetry"},{"key":"R32-20250903","doi-asserted-by":"crossref","first-page":"109148","DOI":"10.1016\/j.apradiso.2020.109148","article-title":"Evaluation of PHITS for microdosimetry in BNCT to support radiobiological research","volume":"161","author":"Hu","year":"2020","journal-title":"Appl Radiat Isot"},{"issue":"7-8 Suppl","key":"R33-20250903","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.1016\/j.apradiso.2009.03.043","article-title":"Microdosimetry study of THOR BNCT beam using tissue equivalent proportional counter","volume":"67","author":"Hsu","year":"2009","journal-title":"Appl Radiat Isot"},{"key":"R34-20250903","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s12149-016-1121-8","article-title":"Assessment of 10B concentration in boron neutron capture therapy: potential of image-guided therapy using 18FBPA PET","volume":"30","author":"Shimosegawa","year":"2016","journal-title":"Ann Nucl Med"},{"key":"R35-20250903","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1021\/acs.molpharmaceut.1c00882","article-title":"Dodecaborate-encapsulated extracellular vesicles with modification of cell-penetrating peptides for enhancing macropinocytotic cellular uptake and biological activity in Boron Neutron Capture Therapy","volume":"19","author":"Hirase","year":"2022","journal-title":"Mol Pharm"},{"key":"R36-20250903","doi-asserted-by":"crossref","first-page":"8050","DOI":"10.3390\/ijms22158050","article-title":"Development of MRI-detectable boron-containing gold nanoparticle-encapsulated biodegradable polymeric matrix for Boron Neutron Capture Therapy (BNCT)","volume":"22","author":"Wu","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R37-20250903","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s41824-022-00156-z","article-title":"Exploration of the threshold SUV for diagnosis of malignancy using 18F-FBPA PET\/CT","volume":"6","author":"Isohashi","year":"2022","journal-title":"Eur J Hybrid Imaging"},{"key":"R38-20250903","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1097\/RLU.0000000000002926","article-title":"Tumor SUVs on 18F-FDG PET\/CT and aggressive pathological features in esophageal squamous cell carcinoma","volume":"45","author":"Lim","year":"2020","journal-title":"Clin Nucl Med"},{"key":"R39-20250903","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13058-018-0944-8","article-title":"The hypoxic tumor microenvironment in vivo selects the cancer stem cell fate of breast cancer cells","volume":"20","author":"Kim","year":"2018","journal-title":"Breast Cancer Res"},{"key":"R40-20250903","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s13014-017-0939-0","article-title":"Overcoming hypoxia-induced tumor radioresistance in non-small cell lung cancer by targeting DNA-dependent protein kinase in combination with carbon ion irradiation","volume":"12","author":"Klein","year":"2017","journal-title":"Radiat Oncol"},{"key":"R41-20250903","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.3390\/cancers15184494","article-title":"Carbon ions for hypoxic tumors: are we making the most of them?","volume":"15","author":"Sokol","year":"2023","journal-title":"Cancers (Basel)"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T21:00:39Z","timestamp":1756933239000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006047","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"2025-04-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}